Why More Prescribers Do Not Automatically Mean Reliable Treatment Access

The question in this series is whether expanded buprenorphine prescribing becomes reliable treatment access for people with opioid use disorder. The evidence supports a direct answer with an important boundary: more prescribers can widen the opportunity to enter treatment, but they do not guarantee that a pharmacy can fill the prescription before the patient runs out. To judge an access expansion honestly, separate the upstream capacity to write a prescription from the downstream ability to dispense it on time and sustain continuity.

That answer is a systems conclusion, not a measured estimate of what a specific increase in prescribers caused. The two sources do not compare prescriber counts with pharmacy outcomes. They show why the link cannot be assumed. CDC data describe annual retail dispensing activity across the country. The JAMA Network Open study records patient-reported fill barriers in a defined telemedicine sample. Together, they reveal a gap between activity that is visible in aggregate and reliability that is experienced at the point of care.

The apparent contradiction is a difference in layers

The CDC map reports that the national buprenorphine dispensing rate was relatively stable from 2019 through 2024 and reached 4.5 prescriptions per 100 people in 2024, representing more than 15 million prescriptions. It also shows wide state variation, from a listed rate of 24.9 per 100 people in West Virginia to 1.2 in Iowa. These numbers matter. A health system cannot provide medication without prescriptions being dispensed, and the map can reveal where retail dispensing activity is concentrated or sparse.

But an annual rate of prescriptions per 100 residents is not a count of patients with continuous treatment. It includes new and refilled retail prescriptions, uses projected totals from a large pharmacy sample, assigns geography by prescriber location, and excludes mail-order prescriptions. It does not show whether a prescription was filled on the first attempt, whether a pharmacy had to order the drug, whether insurance delayed payment, or how many days a patient waited. It is a surveillance measure for a defined retail channel, not a patient-level reliability measure.

The JAMA study looks at a different layer. Among 601 adults receiving low-barrier telemedicine treatment for opioid use disorder in five states, 192, or 31.9%, reported going without buprenorphine in the previous year because of a pharmacy-related barrier. Another 165, or 27.5%, reported a problem filling a prescription. Among those 165, the leading reported problem was that the pharmacy needed to order the medication, at 54.5%; insurance barriers accounted for 22.4%, and hesitancy about filling a telemedicine prescription accounted for 19.4%.

There is no contradiction between a large annual dispensing total and frequent patient-reported barriers. They use different denominators, time scales, and outcomes. The CDC measure asks how much retail prescription activity was estimated over a year relative to the resident population. The survey asks whether people in a particular telemedicine practice encountered a problem and, in some cases, went without medication while it was being resolved. A prescription can eventually appear in the annual total after a patient has spent days searching for stock. The two observations can both be accurate.

The same reasoning explains why a relatively stable national rate does not prove that access is static. Changes in prescribing capacity, patient need, refill behavior, pharmacy participation, and barriers could offset one another in an aggregate measure. A state rate can rise because established patients receive more refills, because more patients enter treatment, or because several conditions change together. The map does not identify which explanation applies. A patient-level interruption can remain invisible inside a completed annual dispensing event.

The title's “more prescribers” therefore refers to an upstream expansion of potential treatment, not a source-measured number in these materials.